Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GALT $11.61 1.3300 +12.94%
PVCT $2.32 0.2100 +9.95%
SRNE $10.55 0.9000 +9.33%
AMBI $6.94 0.5300 +8.27%
CYTR $3.23 0.2300 +7.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

INO $2.52 -0.1500 -5.62%
THLD $3.83 -0.1900 -4.73%
INFI $10.15 -0.4500 -4.25%
NYMX $5.04 -0.2199 -4.18%
KPTI $31.09 -1.3100 -4.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

U.S. FDA Gets Tougher with Certain Drug Trials

(Reuters) August 27, 2010 - The U.S. Food and Drug Administration is cracking down on use of certain clinical trials that show a new drug is no worse than another already on the market, according to a government report released on Friday.
read article 

Genzyme Rejects Sanofi's $18.5B Offer

(TheStreet) August 30, 2010 - Genzyme has rejected Sanofi-Aventis' $18.5 billion takeover offer, prompting Sanofi's chief executive to accuse Genzyme's management of "stonewalling" negotiations and having "unrealistic" expectations about the biotech company's value.
read article 

Sanofi's Experimental Oral Multiple Sclerosis Treatment Reduces Relapses

(Bloomberg) August 30, 2010 – Sanofi-Aventis SA’s experimental oral medicine teriflunomide significantly reduced the relapse rate in multiple sclerosis patients, meeting the goal of a late- stage study.
read article 

Only 2% of Hospitals Could Have Met ‘Meaningful Use’ in 2009

(Wall Street Journal Health Blog) August 27, 2010 - Despite all the talk about digitizing the health-care world, only 11.9% of U.S. hospitals had adopted at least basic electronic medical records by last year, and only about 2% had done enough to qualify for future government financial incentives, a study finds.
read article (paid subscription required) 

Roche Says No Decision on Job Cuts This Week

(ABC News) August 29, 2010 - Swiss drugmaker Roche Holding AG said on Sunday it would not make any decision on job cuts this week, after Swiss newspaper Sonntag reported it could be about to cut thousands of positions.
read article 

Roche's Hopes For Speedy Drug Approval Dashed

(DowJones/NASDAQ) August 27, 2010 - Roche Holding AG's hopes for a speedy approval of a new breast cancer drug were dashed Friday after U.S. regulators rejected a priority review of T-DM1, adding another item to the growing list of drug development delays and setbacks at the Swiss pharma giant.
read article 

Novartis Drug Tasigna® Approved in Switzerland After Fast-track Review for Treatment of Patients with Newly Diagnosed Ph+ CML

(MarketWatch) August 27, 2010 - The Swiss health authority Swissmedic has granted approval for Tasigna(R) (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
read article 

NICE Draft Guidance Recommends Bortezomib and Thalidomide for Multiple Myeloma

(NICE) August 26, 2010 - In draft guidance published today (26 August 2010) NICE has recommended two treatments for multiple myeloma.
read press release 

Cocktails Are Next For Cancer-Drug Makers

(Bloomberg Businessweek) August 26, 2010 - A diagnosis of AIDS was a death sentence until the advent of drug cocktails in the 1990s allowed patients to suppress the disease indefinitely. Now scientists say a similar combination strategy may change the course of cancer treatment.
read article 

Atomic-Bomb Survivors May Offer Clues on Cancer Treatment Risks

(Bloomberg) August 26, 2010 - DNA from survivors of the atomic bombs dropped on Hiroshima and Nagasaki 65 years ago may help doctors gauge whether certain cancer treatments can trigger genetic defects that can be passed on to patients’ children.
read article 

In the Common Cold, Scientists Find New Hope for Cancer Treatment

(Time Wellness Blog) August 26, 2010 - New research on viruses may translate into new therapies to beat cancer, scientists say.
read article 

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment

(StreetInsider) August 27, 2010 - Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany.
read article 

Cerulean Pharma Inc. Presents Data on Nanopharmaceutical Development Candidates and Platform Technologies at American Chemical Society National Meeting & Exposition

(Cerulean Pharma) August 25, 2010 – Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean’s lead clinical development candidate, and pre-clinical data on Cerulean’s development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
read press release 

Food Better Than Supplements for Cancer Prevention: Expert

(U.S. News & World Report) August 27, 2010 - Nutritional supplements are popular among Americans but people need to educate themselves and use caution when using these products to try to reduce their risk of cancer, says a University of Texas expert.
read article 

FDA Opens Probe into University of Miami Cancer Research

(Miami Herald) August 27, 2010 - The Food and Drug Administration is investigating cancer studies at the University of Miami after problems were found with one study.
read article 

August 2010 Practice Update (Part Two)

(ASH) August 26, 2010 - ASH submits comments to CMS on proposed changes to Physician Fee Schedule, and more.
read article 

US Oncology Invests in the Development of Physician-Payer Risk Contracting Model with Milliman Assistance

(US Oncology) August 27, 2010 - Innovent Oncology, a subsidiary of US Oncology, has engaged Milliman, a premier global, actuarial and consulting firm, to help develop models in which physician-led oncology organizations can contract around risk, with the intent of negotiating with payers in the first half of 2011.
read press release 

Therapure Biopharma Inc.'s Drug Delivery Program for the Treatment of Cancer and Infectious Disease Receives Support from the National Research Council’s Industrial Reseach

(StreetInsider) August 27, 2010 - Therapure Biopharma Inc. today announced receipt of a financial contribution from the National Research Council’s Industrial Research Assistance Program (NRC-IRAP). The funding is to support Therapure’s drug delivery program for the treatment of liver cancer and hepatitis C infection.
read article 

Three Oncologists, Scientists Join Wilmot Cancer Center Team

(URMC) August 27, 2010 - The University of Rochester Medical Center welcomes three new physician/scientists to serve people with cancer and expand novel research programs at the James P. Wilmot Cancer Center.
read press release 

Letter: A Risk for Cancer Patients

(New York Times) August 26, 2010 - Leaving cancer patients with merely a hope and a prayer that their access to lifesaving cures will not be in jeopardy is too dangerous a gamble.
read article (free registration required) 

Doctors Look for Orange-Size Lump, Find 56-Pounder

(New York Times) August 27, 2010 - Doctors were shocked when they looked into a woman's uterus searching for an orange-size tumor but found something that resembled a giant rock instead.
read article (free registration required) 

Report: Pharma Digital Spending Growing — But Slowly

(Wall Street Journal Health Blog) August 26, 2010 - You can’t watch network TV without being barraged by pharma and OTC drug ads — some best filed under “TMI.” (We live in fear of a Mucinex ad coming on while we’re eating our dinner in front of the tube).
read article (paid subscription required) 

Novartis Gets FDA OK for Blood Pressure Treatment

(Reuters) August 27, 2010 - Swiss drugmaker Novartis AG received U.S. approval for a new treatment of high blood pressure, broadening the use of Tekturna, the successor to the group's best-selling drug, Diovan.
read article 

Federal Court Extends Block On Generic Of Lilly's Strattera

(DowJones/Morningstar) August 27, 2010 - A federal appeals court has extended a temporary order blocking generic versions of Eli Lilly & Co.'s Strattera drug, so arguments can be made for a longer injunction to be in place while the court considers the drug maker's wider appeal of the case.
read article 

Opinion: The Medicare Reform Illusion

(Washington Post) August 27, 2010 - Despite the report from Medicare's trustees this month that the hospital insurance trust fund will not be depleted until 2029, 12 years later than was predicted just last year, Medicare is no better off than it was a year ago.
read article (free registration required)